James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis Poster Number: 541 Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE ...

Sam Finn, a senior research associate at Zymo Research working with the Oncology Diagnostic Team, helped to host this interactive game booth at the “BioFestival” on Tuesday.

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

February 07, 2025--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology ... been accepted for oral and poster presentation at the 21st ...

Feb. 14 - Kojin: Boston biotech Kojin is winding down operations over the next few months, according to a LinkedIn status from the business. In the post, the company said it expects many of its ...

Showcase your company news with guaranteed exposure both in print and online In today's rapidly evolving business landscape, CFOs are pivotal in driving organizational success through ...

This is one of the goals of the French biotechnology company Global Bioenergies, which is working with Audi to produce gasoline from sustainable sources such as wheat straw and wood chips. The Swiss ...